– effective in preventing TB in HIV – positive patients, phase III trials prove to be Significant Milestone in vaccine research Befrom clinical trials in Tanzania show that a new vaccine against tuberculosis, Mycobacterium vaccae is carried out effectively in preventing tuberculosis in humans with HIV infection http://edpillsbox.com edpillsbox.com . Findings from the studies that were conducted by investigators from Dartmouth Medical School in the United States , will be published in the next issue of AIDS, the leading journal in the field of HIV and AIDS research. The journal is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy.

The Dartmouth group began Phase I trials in humans with MS in the United States in 1994 in collaboration with Robert labor, and demonstrated that a multiple – dose series of MV was safe in both healthy volunteers and patients with HIV infection. The group then phase II studies conducted in larger groups of patients in Zambia and in Finland. In the Zambian study found Richard Waddell, a research assistant professor at Dartmouth Medical School found that MV enhanced immune response against tuberculosis. Subsequently received the Dartmouth group means from the National Institutes of Health large large Phase III efficacy trial in Tanzania, under the direction of Lillian MTEI, in Dar es Salaam. – The Dardar Health Study We are pleased and Dar Es Salaam, Tanzania called, found that MV immunization. Reduced the rate of definite tuberculosis by 39 % among 2,000 HIV-infected patients in Tanzania Since newly-infected HIV patients risk contracting TB almost immediately Dartmouth investigators are targeting a strategy for the management of MV before patients need to start taking ARVs.

Is expected an Investigational New Drug apply To AVI-4658 in Duchenne.